Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Atezolizumab
Indication/Tumor Type bladder urothelial carcinoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive bladder urothelial carcinoma sensitive Atezolizumab Phase II Actionable In a Phase II trial (IMvigor210), treatment with Tecentriq (atezolizumab) resulted in an objective response rate (ORR) of 23% (27/119) in cisplatin-ineligible patients with previously untreated, locally advanced or metastatic urothelial cancer, and ORR was 28% (9/32, 4 complete responses, 5 partial responses) in patients with immune cell CD274 (PD-L1) expression greater than or equal to 5% (PMID: 27939400; NCT02108652). 27939400
CD274 positive bladder urothelial carcinoma sensitive Atezolizumab Guideline Actionable Tecentriq (atezolizumab) is included in guidelines as a first-line therapy (category 2B) for cisplatin-ineligible bladder urothelial carcinoma patients with immune cell CD274 (PD-L1) expression greater than or equal to 5% (NCCN.org). detail...
PubMed Id Reference Title Details
NCCN.org Full reference...
(27939400) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Full reference...